176 related articles for article (PubMed ID: 26038236)
1. Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping.
Jordan NY; Mimpen JY; van den Bogaard WJ; Flesch FM; van de Meent MH; Torano JS
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jul; 995-996():70-3. PubMed ID: 26038236
[TBL] [Abstract][Full Text] [Related]
2. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
3. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva.
Begas E; Kouvaras E; Tsakalof AK; Bounitsi M; Asprodini EK
Biomed Chromatogr; 2015 Nov; 29(11):1657-63. PubMed ID: 25891161
[TBL] [Abstract][Full Text] [Related]
5. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
6. Quantification of caffeine in human saliva by Nuclear Magnetic Resonance as an alternative method for cytochrome CYP1A2 phenotyping.
Schievano E; Finotello C; Navarini L; Mammi S
Talanta; 2015 Aug; 140():36-41. PubMed ID: 26048820
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
8. An optimized and validated SPE-LC-MS/MS method for the determination of caffeine and paraxanthine in hair.
De Kesel PM; Lambert WE; Stove CP
Talanta; 2015 Nov; 144():62-70. PubMed ID: 26452792
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous quantitation of serum caffeine and its metabolites by ultra-high-performance liquid chromatography-tandem mass spectrometry for CYP1A2 activity prediction in premature infants.
Jiang Z; Gao X; Liang J; Ni S
Biomed Chromatogr; 2021 Sep; 35(9):e5141. PubMed ID: 34041763
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
11. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
12. Salivary caffeine metabolic ratio in alcohol-dependent subjects.
Kukongviriyapan V; Senggunprai L; Prawan A; Gaysornsiri D; Kukongviriyapan U; Aiemsa-Ard J
Eur J Clin Pharmacol; 2004 Apr; 60(2):103-7. PubMed ID: 15022032
[TBL] [Abstract][Full Text] [Related]
13. The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS.
Lajin B; Schweighofer N; Goessler W; Obermayer-Pietsch B
Talanta; 2021 Nov; 234():122658. PubMed ID: 34364467
[TBL] [Abstract][Full Text] [Related]
14. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
15. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease and CYP1A2 activity.
Forsyth JT; Grünewald RA; Rostami-Hodjegan A; Lennard MS; Sagar HJ; Tucker GT
Br J Clin Pharmacol; 2000 Oct; 50(4):303-9. PubMed ID: 11012552
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Quantification of Antioxidants Paraxanthine and Caffeine in Human Saliva by Electrochemical Sensing for CYP1A2 Phenotyping.
Anastasiadi RM; Berti F; Colomban S; Tavagnacco C; Navarini L; Resmini M
Antioxidants (Basel); 2020 Dec; 10(1):. PubMed ID: 33374269
[TBL] [Abstract][Full Text] [Related]
18. New specific marker of cytochrome P450 1A2 activity.
Filimonova AA; Ziganshina LE; Ziganshin AU; Chichirov AA
Bull Exp Biol Med; 2011 Apr; 150(6):762-4. PubMed ID: 22235437
[TBL] [Abstract][Full Text] [Related]
19. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
20. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
Labedzki A; Buters J; Jabrane W; Fuhr U
Biochem Pharmacol; 2002 Jun; 63(12):2159-67. PubMed ID: 12110375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
